ArticleIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
Assessment of ATTR Cardiac Amyloidosis in Patients with Left Ventricular Hypertrophy Using Tc-99m Pyrophosphate Scintigraphy.
Article in Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Amyloidosis is characterized by the extracellular deposition of fibrillar proteins, leading to tissue damage and dysfunction. Cardiac amyloidosis (CA) occurs when these fibrils accumulate in the heart's extracellular matrix, causing infiltrative cardiomyopathy, heart failure, and potentially death. Early diagnosis is imperative in accurate management. Transthyretin amyloidosis, either hereditary or age-related, is a common cause of CA, often presenting with left ventricular hypertrophy (LVH) and heart failure with preserved ejection fraction (HFpEF). This study investigates the utility of Tc-99 m Pyrophosphate (Tc-99 m PYP) imaging in diagnosing Transthyretin Amyloidosis ((ATTR)-CA) in patients with unexplained LVH. Materials and Methods: This prospective observational study, conducted between January 2023 and June 2024, involved 52 patients with clinical suspicion of CA and left ventricular wall thickness >12 mm. Patients underwent Tc-99 m PYP scintigraphy, and the results were categorized as positive, negative, or equivocal. Results: The study population's mean age was 64.6 years, with a male predominance (69%). Of the 52 patients, 9 (17.3%) had positive, 28 (53.8%) negative, and 15 (28.8%) equivocal Tc-99 m PYP scan results. Echocardiographic features, such as septal hypertrophy and granular speckled appearance, were significantly associated with positive scan findings. Comorbidities such as coronary artery disease and dyslipidemia were also common. Cardiac biomarkers NT-proBNP and troponin I showed elevated levels in patients with positive scan results. Conclusion: Tc-99 m PYP imaging is an effective noninvasive tool for diagnosing ATTR CA, particularly in patients with unexplained LVH. The presence of HFpEF, abnormal ECG, and restrictive features on echocardiography should prompt further investigation for CA. Early diagnosis allows for timely management, improving patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.